Melatonin attenuates methamphetamine-induced neuroinflammation through the melatonin receptor in the SH-SY5Y cell

Pawaris Wongprayoon1, Piyarat Govitrapong2

  • 1Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Salaya, Nakornpathom 73170, Thailand.

Neurotoxicology
|August 19, 2015
PubMed

Insights

Melatonin protects against methamphetamine-induced neuroinflammation by inhibiting TNFα and NFκB activation. This effect is mediated through melatonin receptors, particularly MT2, in SH-SY5Y cells.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Cell Biology

Background:

  • Methamphetamine abuse causes neuroinflammation and cell death.
  • Tumor Necrosis Factor-alpha (TNFα) is implicated in methamphetamine-induced neuroinflammation.
  • Melatonin's anti-neuroinflammatory effects are known, but mechanisms require elucidation.

Purpose of the Study:

  • To investigate methamphetamine's effects on TNFα expression and NFκB activation in SH-SY5Y cells.
  • To explore melatonin's protective mechanisms against methamphetamine-induced neuroinflammation.

Main Methods:

  • Utilized the SH-SY5Y neuroblastoma cell line.
  • Assessed TNFα expression, IκB degradation, and NFκB nuclear translocation.
  • Investigated melatonin's effects with and without luzindole (melatonin receptor antagonist) and MT2 receptor knockdown via siRNA.

Main Results:

  • Methamphetamine time-dependently increased TNFα expression, IκB degradation, and NFκB nuclear translocation.
  • Melatonin pretreatment (100nM) prevented methamphetamine-induced TNFα overexpression and NFκB activation.
  • Luzindole and MT2 knockdown abrogated melatonin's protective effects, indicating receptor-mediated action.

Conclusions:

  • Melatonin mitigates methamphetamine-induced neuroinflammation in SH-SY5Y cells.
  • The protective effects are mediated via membrane receptors, specifically the MT2 subtype.
  • Findings suggest a therapeutic potential for melatonin in methamphetamine-related neuroinflammation.

Related Concept Videos

Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
873
Management of Insomnia01:19

Management of Insomnia

The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
782
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.5K